Skip to content
OpenCapital
Get started

Aurinia Pharmaceuticals AUPH Change in receivables

Change in receivables at other companies

LQD
Liquidia CorporationLQDA
$20.06M+1,463%
Alkermes logo
AlkermesALKS
$23.22M+135%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$1.69B-11,147%

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.39B+78.5%

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInReceivables.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's change in receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's change in receivables?
Aurinia Pharmaceuticals (AUPH) reported change in receivables of $7.72M in Q1 2026.
How has Aurinia Pharmaceuticals's change in receivables changed year-over-year?
Aurinia Pharmaceuticals's change in receivables increased by 102.9% year-over-year, from $3.81M to $7.72M.
What is the long-term trend for Aurinia Pharmaceuticals's change in receivables?
Over 2 years (2021 to 2025), Aurinia Pharmaceuticals's change in receivables has grown at a -42.1% compound annual growth rate (CAGR), from $15.42M to $5.17M.
What does change in receivables mean?
Change in total receivables including trade and non-trade receivables.